Multicenter intervention studies are currently testing the effects of supplemental IGF-1/IGFBP3 in extremely preterm infants on respiratory outcomes and ROP (ClinicalTrials.gov Identifiers NCT03253263 and NCT01096784, respectively; Horsch et al., 2020). The gene discussed is IGF1; the disease is retinopathy of prematurity.